A Phase II, Open-label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab in Patients With Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive After First Line Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Avelumab (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- Acronyms AveNEC
- 31 Aug 2018 Biomarkers information updated
- 22 Dec 2017 Status changed from not yet recruiting to recruiting.
- 22 Nov 2017 Planned End Date changed from 21 May 2023 to 1 Jan 2024.